AIDS Facts

AIDS is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV). By damaging the immune system, HIV interferes with the body's ability to fight off viruses, bacteria and fungi that cause disease. HIV makes an individual more susceptible to certain types of cancers and to infections that the body would normally resist, such as pneumonia and meningitis. The virus and the infection itself are known as HIV. "Acquired immunodeficiency syndrome (AIDS)" is the name given to the later stages of an HIV infection.

 

One of the brutal facts about aids states that an estimated 33 million people have been infected worldwide. And though the spread of the virus has slowed in some countries, it has escalated or remained unchanged in others. The best hope for stemming the spread of HIV lies in prevention, treatment and education.

Why Cytolin®?

 

HIV/AIDS is not curable and for a long time now, drug treatments were simply aimed at prolonging the life of patients with the use of certain drugs that cause the least side effects. The most popular treatment known today is Highly Active Antiretroviral Therapy (HAART). The therapy makes use of three or more medications but it can be costly over the long term. Treating HIV/AIDS is usually a life long proposition.

 

There are several other effective treatments for HIV/AIDS available today but researchers are still trying to develop new and improved drugs to help infected patients live quality lives despite their condition. CytoDyn, Inc. is determined to get FDA approval of their new drug Cytolin® despite the lengthy and expensive process. The company is convinced that Cytolin® could be a very effective new treatment for early HIV infecion before the antiviral drugs are recommended. With the passage of time, more and more people will become aware of this new treatment.

 

Why Cytolin® - The Video


Cytolin® - Immune based Therapy for AIDS

 

 

Cytolin® Overview

Cytolin® is a new drug for treating HIV/AIDS but is it not aimed at killing the virus directly. Instead, the drug is aimed at preventing the human immune system from self destructing in response to HIV infection.

 

The interview with the creator of the new drug provided additional information for those who want to know more about the drug. Cytolin® aims to prevent killer cells stimulated by HIV infection from destroying the CD4 cells, thereby stopping the progression to AIDS. Allen D. Allen, CEO of CytoDyn Inc, and other associates formed the company so that they could continue development of Cytolin®.

 

Cytolin® put to the Test

A test of Cytolin® was carried out in which five HIV-seropositive adults received one infusion of 7 mg Cytolin® in an early pilot study. After five weeks (at study end) there was a resolution of cutaneous anergy across five to six antigens (p<0.5) measured with a standardized device that included a glycerin control. This apparent improvement in cell-mediated immune function was clinically correlated with a resolution of ARC-type complaints, such as molluscum contagiosum. It was also correlated with a reduced mean vial burden that reached a 1-log reduction after 4 weeks, and was maintained for at least another week at study end (see Chart below).

 

Cytolin Testing Results